刚刚！崩盘了

Group 1: Market Overview - The Hong Kong stock market experienced significant volatility on September 16, with a notable stock, Yaojie Ankang-B, seeing a dramatic rise and fall in its share price, peaking at HK$679.5 before plummeting over 50% to below HK$200 [1][3] - The stock's trading volume reached 9.578 million shares, with a turnover of HK$40.21 billion, indicating high market activity and volatility [1] - In the A-share market, the three major indices showed slight increases, with the Shanghai Composite Index rising by 0.04%, the Shenzhen Component Index by 0.45%, and the ChiNext Index by 0.68% [5] Group 2: Yaojie Ankang-B Company Profile - Yaojie Ankang is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, with no commercialized products to date [3] - The company reported zero revenue for the first half of the year and a loss of 1.23 billion RMB [3] - The stock surged due to the announcement of a Phase II clinical trial for its core product, TT-00420, which received implicit approval from the Chinese National Medical Products Administration [3] Group 3: Stock Performance and Trends - The stock's market capitalization reached HK$790.62 billion, with a total share capital of 397 million shares, of which only 15.281 million shares are available for trading, contributing to its price volatility [3] - The stock's price fluctuation was attributed to its small float, allowing minor capital inflows to significantly impact its price [3] - In the A-share market, 3,629 stocks rose, with 88 hitting the daily limit up, while 1,689 stocks declined [6][7]